Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates

12 August 2026 · By · Wire by Fusion42

Published

12 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at biospace.com →

◆ Verified

Fusion42 · 22 August 2026 · Fusion42 review

Can-Fite BioPharma's lead drug candidates, Piclidenoson and Namodenoson, are in Phase III clinical trials with advanced regulatory status including FDA Fast Track and Orphan Drug designations, positioning them for potential marketing approval in the US and Europe.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You must prepare for entry into US and European markets as this regulatory clarity cuts development risk. The Fast Track and Orphan designations open accelerated approval routes for your oncology or inflammatory disease treatments.

◆ Coverage

1 source · 12 Aug 2026

◆ Related on Wire

◆ Topics

Biotechphase-iii-trialsfda-fast-trackorphan-drugregulatory-approvaloncologyinflammatory-disease